Open Nav

ArtGene Therapeutics

  • Scott Maguire

Raising up to $7M for pre-clinical and phase 1

  • Date:Wednesday, October 17
  • Time:11:30 AM - 11:45 AM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:ArtGene Therapeutics is a pre-clinical stage company that is developing non-viral gene therapy targeted against cardiovascular diseases. Our lead drug candidate - ART-101 - is a 2nd generation of Neovasculgen - an approved and used drug in Russia. It has same mechanism of action and active molecule, thus is a de-risked project guaranteed to be safe and effective.
  • Company Website:http://www.artgentx.com/technology/
  • Company HQ City:Rockville
  • Company HQ Country:United States
  • Company HQ State:Maryland                  
  • Main Therapeutic Focus:Gene/Cell Therapy
  • Lead Product in Development :ART-101
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :1
  • Additional Information/Comments:Neovasculgen is a gene therapy drug that was developed by Human Stem Cells Institute and approved in 2012 in Russia. To date the drug is used in more than 500 hospitals in Russia, ~3000 patients already treated. Drug proved its safety and is 3-5 times more effective than any other treatment. Artgen is developing improved version of Neovasculgen. The difference between two drugs is a small mutation that is responsible for mRNA half-life time, while active molecule and mechanism of action is exactly the same. This change was made to increase patent lifetime and potentially efficacy to make the project attractive for US market. Please contact bezel.egor@hsci.ru for more information
  • Previous and Current Investors:HSCI
  • Size of Last Investment Round:200.000 USD
  • Total Amount Raised to Date, In All Rounds:400.000 USD
Speakers
Back